BR0212446A - Uso de 4-piridilmetilftalazinas para tratamento de câncer - Google Patents

Uso de 4-piridilmetilftalazinas para tratamento de câncer

Info

Publication number
BR0212446A
BR0212446A BR0212446-7A BR0212446A BR0212446A BR 0212446 A BR0212446 A BR 0212446A BR 0212446 A BR0212446 A BR 0212446A BR 0212446 A BR0212446 A BR 0212446A
Authority
BR
Brazil
Prior art keywords
pyridylmethylphthalazine
cancer treatment
treated
patients
antiangiogenesis agent
Prior art date
Application number
BR0212446-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Margaret Han Dugan
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0212446A publication Critical patent/BR0212446A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR0212446-7A 2001-09-12 2002-09-11 Uso de 4-piridilmetilftalazinas para tratamento de câncer BR0212446A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31869401P 2001-09-12 2001-09-12
US33102501P 2001-09-12 2001-09-12
US32204401P 2001-09-14 2001-09-14
US38816302P 2002-06-12 2002-06-12
PCT/EP2002/010194 WO2003022282A1 (en) 2001-09-12 2002-09-11 Use of 4-pyridylmethylphthalazines for cancer treatment

Publications (1)

Publication Number Publication Date
BR0212446A true BR0212446A (pt) 2004-08-17

Family

ID=27502161

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212446-7A BR0212446A (pt) 2001-09-12 2002-09-11 Uso de 4-piridilmetilftalazinas para tratamento de câncer

Country Status (22)

Country Link
US (2) US20040258770A1 (cg-RX-API-DMAC7.html)
EP (1) EP1427420B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005502690A (cg-RX-API-DMAC7.html)
KR (1) KR20040029172A (cg-RX-API-DMAC7.html)
CN (1) CN1330308C (cg-RX-API-DMAC7.html)
AT (2) ATE329597T1 (cg-RX-API-DMAC7.html)
AU (2) AU2002342678B2 (cg-RX-API-DMAC7.html)
BR (1) BR0212446A (cg-RX-API-DMAC7.html)
CA (1) CA2457848A1 (cg-RX-API-DMAC7.html)
CO (1) CO5560545A2 (cg-RX-API-DMAC7.html)
CY (1) CY1105189T1 (cg-RX-API-DMAC7.html)
DE (2) DE60231068D1 (cg-RX-API-DMAC7.html)
DK (1) DK1427420T3 (cg-RX-API-DMAC7.html)
ES (2) ES2266590T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20040241A2 (cg-RX-API-DMAC7.html)
IL (1) IL160382A0 (cg-RX-API-DMAC7.html)
NO (1) NO327358B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ531484A (cg-RX-API-DMAC7.html)
PL (1) PL367349A1 (cg-RX-API-DMAC7.html)
PT (1) PT1427420E (cg-RX-API-DMAC7.html)
RS (1) RS16804A (cg-RX-API-DMAC7.html)
WO (1) WO2003022282A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
WO2005027972A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
KR101037292B1 (ko) * 2010-09-03 2011-05-27 (주)슈추어 신발 장식구

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0722936B1 (en) * 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
KR100489174B1 (ko) * 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion

Also Published As

Publication number Publication date
NO327358B1 (no) 2009-06-15
HRP20040241A2 (en) 2005-04-30
CN1553803A (zh) 2004-12-08
AU2002342678B2 (en) 2006-08-24
CA2457848A1 (en) 2003-03-20
RS16804A (sr) 2007-02-05
WO2003022282A1 (en) 2003-03-20
AU2006203428B2 (en) 2009-06-04
ATE421880T1 (de) 2009-02-15
ES2320922T3 (es) 2009-05-29
CO5560545A2 (es) 2005-09-30
EP1427420B1 (en) 2006-06-14
PL367349A1 (en) 2005-02-21
NO20040973L (no) 2004-06-03
EP1427420A1 (en) 2004-06-16
US20090196871A1 (en) 2009-08-06
IL160382A0 (en) 2004-07-25
AU2006203428A1 (en) 2006-08-31
NZ531484A (en) 2007-02-23
DE60231068D1 (de) 2009-03-19
US20040258770A1 (en) 2004-12-23
KR20040029172A (ko) 2004-04-03
PT1427420E (pt) 2006-10-31
DE60212415T2 (de) 2006-11-23
CN1330308C (zh) 2007-08-08
CY1105189T1 (el) 2010-03-03
DE60212415D1 (de) 2006-07-27
DK1427420T3 (da) 2006-10-02
ES2266590T3 (es) 2007-03-01
ATE329597T1 (de) 2006-07-15
JP2005502690A (ja) 2005-01-27

Similar Documents

Publication Publication Date Title
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
BR0209269A (pt) Terapia de combinação antiangiogênica para o tratamento de câncer
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
BR9811946A (pt) Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
EA200400235A1 (ru) Комбинированная терапия для лечения рака
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
BR9807418A (pt) Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
EP0944389A4 (en) CLEANED PREPARATIONS FOR 10-PROPARGYL-10-DEAZAAMINE OPTERINE AND METHOD FOR USE IN TUMOR TREATMENT
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
PT1214061E (pt) Nova utilizacao de docetaxel para o tratamento do carcinoma hepatocelular
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer
BR0215389A (pt) Agente preventivo ou terapêutico para distúrbio urinário, método para prevenir ou tratar distúrbio urinário, uso de um composto, composto, pró-droga, processo para preparar o composto, medicamento, e, método para triar um composto
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
BR0215689A (pt) Composição farmacêutica compreendendo arsênico para o tratamento de malignidade
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/50; A61P 35/00; A61P 35/04

Ipc: A61K 31/50 (2011.01), A61P 35/00 (2011.01), A61P 3

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.